214 related articles for article (PubMed ID: 35934006)
21. Final Analysis of a Phase 2 Trial of Once Weekly Hypofractionated Whole Breast Irradiation for Early-Stage Breast Cancer.
Reshko LB; Pan J; Rai SN; Ajkay N; Dragun A; Roberts TL; Riley EC; Quillo AR; Scoggins CR; McMasters KM; Eldredge-Hindy H
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):56-65. PubMed ID: 34710520
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported Long-term Cosmetic Outcomes Following Short Fractionation Whole Breast Radiotherapy With Boost.
Chan EK; Tabarsi N; Tyldesley S; Khan M; Woods R; Speers C; Weir L
Am J Clin Oncol; 2016 Oct; 39(5):473-8. PubMed ID: 24824143
[TBL] [Abstract][Full Text] [Related]
23. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Kunkler IH; Williams LJ; Jack WJ; Cameron DA; Dixon JM;
Lancet Oncol; 2015 Mar; 16(3):266-73. PubMed ID: 25637340
[TBL] [Abstract][Full Text] [Related]
24. Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients.
Karasawa K; Kunogi H; Hirai T; Hojo H; Hirowatari H; Izawa H; Ito K; Sasai K; Kawashima M; Furuya T; Sugimoto S; Kurokawa C; Ozawa S; Saito M
Breast Cancer; 2014 Jul; 21(4):402-8. PubMed ID: 22968629
[TBL] [Abstract][Full Text] [Related]
25. Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.
Ahlawat S; Haffty BG; Goyal S; Kearney T; Kirstein L; Chen C; Moore DF; Khan AJ
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):118-125. PubMed ID: 26700706
[TBL] [Abstract][Full Text] [Related]
26. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
Offersen BV; Alsner J; Nielsen HM; Jakobsen EH; Nielsen MH; Krause M; Stenbygaard L; Mjaaland I; Schreiber A; Kasti UM; Overgaard J;
J Clin Oncol; 2020 Nov; 38(31):3615-3625. PubMed ID: 32910709
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer.
Kim JY; Jung SY; Lee S; Kang HS; Lee ES; Park IH; Lee KS; Ro J; Lee NK; Shin KH
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1037-42. PubMed ID: 24267970
[TBL] [Abstract][Full Text] [Related]
30. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles CE; Griffin CL; Kirby AM; Titley J; Agrawal RK; Alhasso A; Bhattacharya IS; Brunt AM; Ciurlionis L; Chan C; Donovan EM; Emson MA; Harnett AN; Haviland JS; Hopwood P; Jefford ML; Kaggwa R; Sawyer EJ; Syndikus I; Tsang YM; Wheatley DA; Wilcox M; Yarnold JR; Bliss JM;
Lancet; 2017 Sep; 390(10099):1048-1060. PubMed ID: 28779963
[TBL] [Abstract][Full Text] [Related]
31. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
Yu E; Huang D; Leonard K; Dipetrillo T; Wazer D; Hepel J
Clin Breast Cancer; 2017 Dec; 17(8):638-643. PubMed ID: 28629952
[TBL] [Abstract][Full Text] [Related]
33. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.
Veronesi U; Orecchia R; Maisonneuve P; Viale G; Rotmensz N; Sangalli C; Luini A; Veronesi P; Galimberti V; Zurrida S; Leonardi MC; Lazzari R; Cattani F; Gentilini O; Intra M; Caldarella P; Ballardini B
Lancet Oncol; 2013 Dec; 14(13):1269-77. PubMed ID: 24225155
[TBL] [Abstract][Full Text] [Related]
34. Individualised target volume selection and dose prescription after conservative surgery, mastectomy and reconstruction.
Chua BH
Breast; 2019 Nov; 48 Suppl 1():S69-S75. PubMed ID: 31839165
[TBL] [Abstract][Full Text] [Related]
35. Hypofractionated radiotherapy for breast cancer acceleration of the START A treatment regime: intermediate tolerance and efficacy.
Janssen S; Glanzmann C; Lang S; Verlaan S; Streller T; Wisler D; Linsenmeier C; Studer G
Radiat Oncol; 2014 Jul; 9():165. PubMed ID: 25059887
[TBL] [Abstract][Full Text] [Related]
36. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.
Monteau A; Sigal-Zafrani B; Kirova YM; Fourchotte V; Bollet MA; Vincent-Salomon A; Asselain B; Salmon RJ; Fourquet A
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1021-8. PubMed ID: 19386441
[TBL] [Abstract][Full Text] [Related]
37. Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis.
Oses G; Barreto TD; Cases C; Muñoz-Guglielmetti D; Antelo G; Mollà M
Clin Transl Oncol; 2023 Aug; 25(8):2419-2426. PubMed ID: 36947361
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series.
Cante D; Franco P; Sciacero P; Girelli G; Marra AM; Pasquino M; Russo G; Casanova Borca V; Mondini G; Paino O; Numico G; Tofani S; La Porta MR; Ricardi U
Med Oncol; 2014 Feb; 31(2):838. PubMed ID: 24415414
[TBL] [Abstract][Full Text] [Related]
39. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ.
Williamson D; Dinniwell R; Fung S; Pintilie M; Done SJ; Fyles AW
Radiother Oncol; 2010 Jun; 95(3):317-20. PubMed ID: 20400190
[TBL] [Abstract][Full Text] [Related]
40. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
